局部晚期喉癌放化疗的最佳顺序
基于美国国家癌症数据库2004—2013年8154例III/IV期(除外T1)喉癌患者,比较同步放化疗(CCRT)与诱导化疗后放疗/手术(IC)的总生存(OS)。两组5年OS分别为49.9%与50.6%(P=0.653),多因素分析无差异(IC校正HR 0.96,95%CI 0.88-1.04,P=0.268)。放疗剂量≥66 Gy在CCRT组与更好OS相关,但IC组无此关联;诱导化疗开始距放疗43-100天者OS优于21-42天或101-120天者。
要点
- CCRT与IC的5年OS分别为49.9%与50.6%,多因素分析无显著差异。
- 放疗剂量≥66 Gy在CCRT组与更好OS相关,在IC组无此关联。
- 诱导化疗于放疗前43-100天开始者OS优于21-42天或101-120天开始者。
核心结论
- 局部晚期喉癌CCRT与IC的总生存无差异,放疗剂量和诱导化疗距放疗时间为与生存相关的因素。
研究设计与样本
- 基于美国国家癌症数据库的队列研究,纳入2004—2013年美国癌症联合委员会III/IV期(除外T1)喉癌患者8154例,接受CCRT或IC。
主要发现
- 中位随访32.7个月,CCRT与IC的估计5年OS分别为49.9%与50.6%(P=0.653)。
- 多因素分析中两方案无差异(IC校正HR 0.96,95%CI 0.88-1.04,P=0.268)。
- 放疗剂量≥66 Gy在CCRT组整体与更好OS相关,在IC组无此关联。
- 接受≥66 Gy的患者中,CCRT与IC的OS无差异(校正HR 0.97,95%CI 0.89-1.06,P=0.552)。
- 诱导化疗于放疗前21-42天或101-120天开始者,OS劣于43-100天开始者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the optimal sequencing of chemoradiotherapy for locally advanced laryngeal cancer. The hypothesis was that concurrent chemoradiotherapy (CCRT) would be associated with improved overall survival (OS) compared to induction chemotherapy followed by radiotherapy (RT)/surgery (IC). METHODS: The National Cancer Database identified 8,154 patients with American Joint Commission on Cancer stage III/IV (excluding T1) laryngeal cancer between 2004 and 2013 treated with one of the established organ preservation techniques: CCRT or IC. The association between OS and total radiation dose (< 66 gray [Gy] or ≥ 66 Gy) was analyzed using the Kaplan-Meier method, as was the association between OS and timing of IC (21-42, 43-100, or 101-120 days before RT). Hazard ratios (HR) adjusted for patient and clinical characteristics were computed using Cox regression modeling. RESULTS: The median follow-up was 32.7 months. The estimated 5-year OS for CCRT and IC was 49.9% and 50.6%, respectively (P = 0.653). On multivariate analysis, no difference was observed between the two regimens (IC, adjusted HR 0.96, 95% confidence interval [CI] 0.88-1.04, P = 0.268). Radiation dose ≥66 Gy had improved OS overall in CCRT group but not in IC patients. When comparing CCRT and IC in patients receiving ≥66 Gy, there was no difference in OS (adjusted HR 0.97, 95% CI 0.89-1.06, P = 0.552). Patients starting chemotherapy 21 to 42 or 101 to 120 days prior to RT had inferior OS compared to patients starting between 43 to 100 days. CONCLUSION: For locally advanced laryngeal cancer, there is no difference in OS between CCRT and IC. Factors associated with survival included radiation dose and timing of induction chemotherapy before RT. LEVEL OF EVIDENCE: 3b Laryngoscope, 129:2313-2320, 2019.
引用
- Shah NK, Qureshi MM, Dyer MA, et al. Optimal sequencing of chemoradiotherapy for locally advanced laryngeal cancer. Laryngoscope. 2019. PMID: 30628077. doi:10.1002/lary.27771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。